TY - JOUR
T1 - Amisulpride switching in schizophrenic patients who showed suboptimal effect and/or tolerability to current antipsychotics in a naturalistic setting
T2 - An explorative study
AU - Kim, Yongmin
AU - Wang, Sheng Min
AU - Kwak, Kyung Phil
AU - Yoon, Ho Kyoung
AU - Pae, Chi Un
AU - Kim, Jung Jin
AU - Bahk, Won Myong
N1 - Publisher Copyright:
Copyright © 2016, Korean College of Neuropsychopharmacology.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2016/11
Y1 - 2016/11
N2 - Objective: Despite numerous atypical antipsychotics (AAP) available, many patients with schizophrenia still experience lack of efficacy and persistent side-effects. Switching from one AAP to another with a different side-effect profile has become a common clinical strategy. We aimed to investigate effect of switching to amisulpride in patients who showed suboptimal effect and /or tolerability to current antipsychotics treatment. Methods: This was a 6-week, prospective, multicenter, open-label, flexible-dose study in patients with schizophrenia. Switching to amisulpride was achieved using cross-titration within 7 days (day 1: 300 mg on day 1 then flexibly dosed 400-800 mg/day). The primary end-point measure was proportion of patients achieving improvement in clinical benefit at week 6 based on Clinical Global Impressions-Clinical Benefit (CGI-CB). Secondary endpoints included change in scores in CGI-CB, CGI-Severity (CGI-S), Subjective Satisfaction Scores (SSS), Brief Psychiatric Rating Scale (BPRS), and Simpson and Angus Rating Scale. Results: Among 37 patients switched to amisulpride, 76% completed study and 56.8% had clinical benefit measure by CGI-CB. CGI-CB and CGI-S scores showed significant improvement at week 6 compared to baseline (mean changes of CGI-CB and CGI-S scores: -1.7+1.0, p<0.0001 and -0.6±0.0, p=0.001, respectively). SSS scores also improved significantly (mean change: 2.1±2.6, p<0.0001). Mean weight of patients significantly lowered compared to baseline (mean change: -1.2±2.0, p<0.0001). Conclusion: Patients with schizophrenia who showed suboptimal efficacy or tolerability with their current antipsychotics and thereby switched to amisulpride resulted in clinical benefit in terms of both improved efficacy and tolerability. The small sample size limits generalizability of the study results.
AB - Objective: Despite numerous atypical antipsychotics (AAP) available, many patients with schizophrenia still experience lack of efficacy and persistent side-effects. Switching from one AAP to another with a different side-effect profile has become a common clinical strategy. We aimed to investigate effect of switching to amisulpride in patients who showed suboptimal effect and /or tolerability to current antipsychotics treatment. Methods: This was a 6-week, prospective, multicenter, open-label, flexible-dose study in patients with schizophrenia. Switching to amisulpride was achieved using cross-titration within 7 days (day 1: 300 mg on day 1 then flexibly dosed 400-800 mg/day). The primary end-point measure was proportion of patients achieving improvement in clinical benefit at week 6 based on Clinical Global Impressions-Clinical Benefit (CGI-CB). Secondary endpoints included change in scores in CGI-CB, CGI-Severity (CGI-S), Subjective Satisfaction Scores (SSS), Brief Psychiatric Rating Scale (BPRS), and Simpson and Angus Rating Scale. Results: Among 37 patients switched to amisulpride, 76% completed study and 56.8% had clinical benefit measure by CGI-CB. CGI-CB and CGI-S scores showed significant improvement at week 6 compared to baseline (mean changes of CGI-CB and CGI-S scores: -1.7+1.0, p<0.0001 and -0.6±0.0, p=0.001, respectively). SSS scores also improved significantly (mean change: 2.1±2.6, p<0.0001). Mean weight of patients significantly lowered compared to baseline (mean change: -1.2±2.0, p<0.0001). Conclusion: Patients with schizophrenia who showed suboptimal efficacy or tolerability with their current antipsychotics and thereby switched to amisulpride resulted in clinical benefit in terms of both improved efficacy and tolerability. The small sample size limits generalizability of the study results.
KW - Amisulpride
KW - Antipsychotic agents
KW - Clinical benefit
KW - Switch
UR - http://www.scopus.com/inward/record.url?scp=84992520797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992520797&partnerID=8YFLogxK
U2 - 10.9758/cpn.2016.14.4.371
DO - 10.9758/cpn.2016.14.4.371
M3 - Article
AN - SCOPUS:84992520797
VL - 14
SP - 371
EP - 377
JO - Clinical Psychopharmacology and Neuroscience
JF - Clinical Psychopharmacology and Neuroscience
SN - 1738-1088
IS - 4
ER -